JP2018534311A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018534311A5 JP2018534311A5 JP2018525700A JP2018525700A JP2018534311A5 JP 2018534311 A5 JP2018534311 A5 JP 2018534311A5 JP 2018525700 A JP2018525700 A JP 2018525700A JP 2018525700 A JP2018525700 A JP 2018525700A JP 2018534311 A5 JP2018534311 A5 JP 2018534311A5
- Authority
- JP
- Japan
- Prior art keywords
- dose
- raf
- inhibitor
- administered
- medicament according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 38
- 102000018471 Proto-Oncogene Proteins B-raf Human genes 0.000 claims 28
- 108010091528 Proto-Oncogene Proteins B-raf Proteins 0.000 claims 28
- 239000003112 inhibitor Substances 0.000 claims 23
- 201000001441 melanoma Diseases 0.000 claims 15
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 10
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 10
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 10
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 10
- 229940124647 MEK inhibitor Drugs 0.000 claims 7
- 229960002271 cobimetinib Drugs 0.000 claims 7
- RESIMIUSNACMNW-BXRWSSRYSA-N cobimetinib fumarate Chemical group OC(=O)\C=C\C(O)=O.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F RESIMIUSNACMNW-BXRWSSRYSA-N 0.000 claims 7
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims 7
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical group CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims 5
- 229960003862 vemurafenib Drugs 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 229960003852 atezolizumab Drugs 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- -1 (S)-[3,4-difluoro-2- (2-fluoro-4-iodophenylamino) phenyl] [3-hydroxy-3- (piperidin-2-yl) azetidin-1-yl ] Chemical group 0.000 claims 2
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 208000021039 metastatic melanoma Diseases 0.000 claims 2
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 230000005723 MEK inhibition Effects 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000011275 oncology therapy Methods 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical group CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562257645P | 2015-11-19 | 2015-11-19 | |
| US62/257,645 | 2015-11-19 | ||
| PCT/US2016/062859 WO2017087851A1 (en) | 2015-11-19 | 2016-11-18 | Methods of treating cancer using b-raf inhibitors and immune checkpoint inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018534311A JP2018534311A (ja) | 2018-11-22 |
| JP2018534311A5 true JP2018534311A5 (enExample) | 2019-12-26 |
| JP6952691B2 JP6952691B2 (ja) | 2021-10-20 |
Family
ID=57485956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018525700A Active JP6952691B2 (ja) | 2015-11-19 | 2016-11-18 | Ｂ−ｒａｆ阻害剤及び免疫チェックポイント阻害剤を使用してがんを治療する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20180256552A1 (enExample) |
| EP (1) | EP3377107B1 (enExample) |
| JP (1) | JP6952691B2 (enExample) |
| KR (1) | KR102702851B1 (enExample) |
| CN (2) | CN108136022A (enExample) |
| AU (1) | AU2016355320B2 (enExample) |
| ES (1) | ES2824120T3 (enExample) |
| HK (1) | HK1256367A1 (enExample) |
| IL (1) | IL259055B (enExample) |
| MX (1) | MX377351B (enExample) |
| PL (1) | PL3377107T3 (enExample) |
| WO (1) | WO2017087851A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| MX383614B (es) | 2015-05-21 | 2025-03-14 | Harpoon Therapeutics Inc | Proteinas de union triespecificas y metodos de uso. |
| AR107303A1 (es) | 2016-01-08 | 2018-04-18 | Hoffmann La Roche | Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| US10100106B2 (en) | 2016-05-20 | 2018-10-16 | Harpoon Therapeutics, Inc. | Single domain serum albumin binding protein |
| CN110291089B (zh) | 2017-01-17 | 2022-05-27 | 海帕瑞吉尼克斯股份有限公司 | 用于促进肝再生或者减少或预防肝细胞死亡的蛋白激酶抑制剂 |
| BR112019025188A2 (pt) * | 2017-06-01 | 2020-06-23 | Cytomx Therapeutics, Inc. | Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| SI3694529T1 (sl) | 2017-10-13 | 2024-10-30 | Harpoon Therapeutics, Inc. | Trispecifične beljakovine in načini uporabe |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| EP3856771A4 (en) | 2018-09-25 | 2022-06-29 | Harpoon Therapeutics, Inc. | Dll3 binding proteins and methods of use |
| WO2020079581A1 (en) * | 2018-10-16 | 2020-04-23 | Novartis Ag | Tumor mutation burden alone or in combination with immune markers as biomarkers for predicting response to targeted therapy |
| WO2021016228A1 (en) * | 2019-07-22 | 2021-01-28 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Combination therapy for treating ras-mutant cancers |
| WO2022131667A1 (ko) * | 2020-12-18 | 2022-06-23 | 경희대학교 산학협력단 | Oligodendrocyte transcription factor 2 억제제를 유효성분으로 포함하는 흑색종 치료 효과 증진용 약학적 조성물 |
| US20240239895A1 (en) * | 2021-04-09 | 2024-07-18 | Genentech, Inc. | Combination therapy with a raf inhibitor and a pd-1 axis inhibitor |
| WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
| WO2025059162A1 (en) | 2023-09-11 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Car-engager containing il-2 variants to enhance the functionality of car t cells |
| WO2025235862A1 (en) | 2024-05-10 | 2025-11-13 | Inndura Therapeutics Inc. | A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| TW200639163A (en) | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| DK2395004T3 (en) | 2005-06-22 | 2016-03-21 | Plexxikon Inc | Pyrrolo [2,3-b] pyridine derivatives as protein kinase inhibitors |
| CA2612241C (en) | 2005-07-01 | 2018-11-06 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| CN103524392B (zh) | 2005-10-07 | 2018-06-01 | 埃克塞利希斯股份有限公司 | 作为用于治疗增生性疾病的mek 抑制剂的吖丁啶 |
| RU2531758C2 (ru) | 2008-02-11 | 2014-10-27 | Куретек Лтд. | Моноклональные антитела для лечения опухолей |
| WO2009111277A1 (en) | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Imdizo [4. 5-b] pyridine derivatives used as raf inhibitors |
| EP2265574A1 (en) | 2008-02-29 | 2010-12-29 | Array Biopharma, Inc. | N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer |
| EP2265610B1 (en) | 2008-02-29 | 2012-12-12 | Array Biopharma, Inc. | Pyrazole [3, 4-b]pyridine raf inhibitors |
| CN102015707A (zh) | 2008-02-29 | 2011-04-13 | 阵列生物制药公司 | Raf抑制剂化合物及其使用方法 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| JP2012500652A (ja) | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | 標的化共刺激ポリペプチドおよび癌を処置するための使用方法 |
| EP4209510B1 (en) | 2008-12-09 | 2024-01-31 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
| NO2504364T3 (enExample) | 2009-11-24 | 2018-01-06 | ||
| JP6335169B2 (ja) * | 2012-08-17 | 2018-05-30 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | コビメチニブ及びメベムラフェニブを投与することを含むメラノーマの併用療法 |
| WO2014193898A1 (en) * | 2013-05-31 | 2014-12-04 | Merck Sharp & Dohme Corp. | Combination therapies for cancer |
| CN105658206A (zh) * | 2013-06-03 | 2016-06-08 | 诺华股份有限公司 | 抗pd-l1抗体与mek抑制剂和/或braf抑制剂的组合 |
-
2016
- 2016-11-18 PL PL16806416T patent/PL3377107T3/pl unknown
- 2016-11-18 MX MX2018006152A patent/MX377351B/es active IP Right Grant
- 2016-11-18 JP JP2018525700A patent/JP6952691B2/ja active Active
- 2016-11-18 CN CN201680051333.4A patent/CN108136022A/zh active Pending
- 2016-11-18 ES ES16806416T patent/ES2824120T3/es active Active
- 2016-11-18 AU AU2016355320A patent/AU2016355320B2/en active Active
- 2016-11-18 WO PCT/US2016/062859 patent/WO2017087851A1/en not_active Ceased
- 2016-11-18 EP EP16806416.0A patent/EP3377107B1/en active Active
- 2016-11-18 KR KR1020187016785A patent/KR102702851B1/ko active Active
- 2016-11-18 HK HK18115456.5A patent/HK1256367A1/zh unknown
- 2016-11-18 CN CN202510876831.3A patent/CN121154828A/zh active Pending
-
2018
- 2018-04-30 IL IL259055A patent/IL259055B/en unknown
- 2018-05-18 US US15/984,067 patent/US20180256552A1/en not_active Abandoned
-
2019
- 2019-11-13 US US16/683,082 patent/US20200155520A1/en not_active Abandoned
-
2023
- 2023-12-18 US US18/544,236 patent/US20240115555A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7194022B2 (ja) | Ｎｏｔｃｈ阻害剤とＰＤ－１またはＰＤ－Ｌ１阻害剤との併用療法 | |
| CN102089007B (zh) | (a)磷酸肌醇3-激酶抑制剂和(b)ras/raf/mek通路调节剂的组合产品 | |
| JP2017529382A5 (enExample) | ||
| JP2017502017A5 (enExample) | ||
| JP2017522307A5 (enExample) | ||
| JP2014509657A5 (enExample) | ||
| JP2013539767A5 (enExample) | ||
| JP2019511526A5 (enExample) | ||
| RU2017102319A (ru) | Прерывистое введение ингибитора mdm2 | |
| JP2014532648A5 (enExample) | ||
| JP2018507243A5 (enExample) | ||
| JP2018519324A5 (enExample) | ||
| Pardanani et al. | A phase I/II study of CYT387, an oral JAK-1/2 inhibitor, in myelofibrosis: significant response rates in anemia, splenomegaly, and constitutional symptoms | |
| WO2018060463A3 (en) | Treatment of prostate cancer | |
| JP2018530578A5 (enExample) | ||
| JP2017502016A5 (enExample) | ||
| US20190290652A1 (en) | Method for treatment of solid malignancies including advanced or metastatic solid malignancies | |
| JP2019526559A5 (enExample) | ||
| JP2021509395A5 (enExample) | ||
| Gibofsky et al. | Lower-dose diclofenac submicron particle capsules provide early and sustained acute patient pain relief in a phase 3 study | |
| Dunne et al. | A phase 1 study to assess the pharmacokinetics of sulopenem etzadroxil (PF-03709270) | |
| JP2016505050A5 (enExample) | ||
| JP2020519576A5 (enExample) | ||
| JP2021505669A5 (enExample) | ||
| WO2006060731A3 (en) | Use of atazanavir for improving the pharmacokinetics of drugs metabolized by ugt1a1 |